Literature DB >> 21632564

Lack of type-specific concordance between human papillomavirus (HPV) serology and HPV DNA detection in the uterine cervix and oral mucosa.

A E Paaso1, K Louvanto2,1, K J Syrjänen3, T Waterboer4, S E Grénman2, M Pawlita4, S M Syrjänen1.   

Abstract

There is limited knowledge about longitudinal genotype-specific concordance between human papillomavirus (HPV) serology and co-existent presence of HPV DNA in the uterine cervix. The role of oral HPV infections in inducing serological response is unclear, as is the effect of HPV antibodies on the outcome of oral HPV infections. The present study is part of the Finnish Family HPV Study designed to evaluate dynamics of HPV infections within families. Here, we correlated the point prevalence of HPV6, 11, 16, 18 and 45 antibodies and concomitant genotype-specific HPV DNA detection in cervical and oral samples of 323 mothers during their 3 year (mean 37.5 months) follow-up. The mean age of these pregnant mothers at enrolment (third trimester) was 25.5 years. HPV antibodies were analysed with multiplex HPV serology and HPV genotyping was performed using a Multimetrix kit (Progen Biotechnik). There was no concordance between cervical DNA detection and co-existent seropositivity, and the same was true even in samples taken 12 months apart. Women who cleared their cervical HPV16 infection had the highest HPV16 antibody levels, whereas those who acquired incident HPV16 infections had the lowest antibody levels. Neither the presence nor the dynamics of oral HPV DNA had any correlation with HPV serology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632564     DOI: 10.1099/vir.0.032011-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  18 in total

1.  Determinants of High-Risk Human Papillomavirus Seroprevalence and DNA Prevalence in Mid-Adult Women.

Authors:  Patricia Sadate-Ngatchou; Joseph J Carter; Stephen E Hawes; Qinghua Feng; Taylor Lasof; Joshua E Stern; Tsung-Chieh Jane Fu; Denise A Galloway; Laura A Koutsky; Rachel L Winer
Journal:  Sex Transm Dis       Date:  2016-03       Impact factor: 2.830

2.  Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men.

Authors:  Beibei Lu; Raphael P Viscidi; Yougui Wu; Alan G Nyitray; Luisa L Villa; Eduardo Lazcano-Ponce; Roberto J Carvalho da Silva; Maria Luiza Baggio; Manuel Quiterio; Jorge Salmerón; Danelle C Smith; Martha Abrahamsen; Mary Papenfuss; Anna R Giuliano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-07-03       Impact factor: 4.254

3.  High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study.

Authors:  Jean-Luc Prétet; Véronique Dalstein; Antoine Touzé; Agnès Beby-Defaux; Patrick Soussan; Élise Jacquin; Philippe Birembaut; Christine Clavel; Christiane Mougin; Alexandra Rousseau; Jean Lacau Saint Guily
Journal:  Clin Exp Med       Date:  2022-02-23       Impact factor: 3.984

4.  Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study.

Authors:  Lauren E Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2013-05-29       Impact factor: 7.396

5.  Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.

Authors:  Anna Paaso; Hanna-Mari Koskimaa; Marij Jp Welters; Seija Grénman; Kari Syrjänen; Sjoerd H van der Burg; Stina Syrjänen
Journal:  J Transl Med       Date:  2015-05-20       Impact factor: 5.531

6.  Anal, penile, and oral high-risk HPV infections and HPV seropositivity in HIV-positive and HIV-negative men who have sex with men.

Authors:  Vera M van Rijn; Sofie H Mooij; Madelief Mollers; Peter J F Snijders; Arjen G C L Speksnijder; Audrey J King; Henry J C de Vries; Arne van Eeden; Fiona R M van der Klis; Hester E de Melker; Marianne A B van der Sande; Maarten F Schim van der Loeff
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

7.  Genotype-specific incidence and clearance of human papillomavirus in oral mucosa of women: a six-year follow-up study.

Authors:  Karolina Louvanto; Jaana Rautava; Jaana Willberg; Lilli Wideman; Kari Syrjänen; Seija Grénman; Stina Syrjänen
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

8.  Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus.

Authors:  Hilary A Robbins; Yan Li; Carolina Porras; Michael Pawlita; Arpita Ghosh; Ana Cecilia Rodriguez; Mark Schiffman; Sholom Wacholder; Troy J Kemp; Paula Gonzalez; John Schiller; Douglas Lowy; Mark Esser; Katie Matys; Wim Quint; Leen-Jan van Doorn; Rolando Herrero; Ligia A Pinto; Allan Hildesheim; Tim Waterboer; Mahboobeh Safaeian
Journal:  BMC Infect Dis       Date:  2014-03-03       Impact factor: 3.090

9.  Human papillomavirus DNA positivity and seropositivity in rural Chinese men and women: a population-based cross-sectional study.

Authors:  Fangfang Liu; Qiuju Deng; Chanyuan Zhang; Yaqi Pan; Ying Liu; Zhonghu He; Min Sun; Mengfei Liu; Jingjing Li; Xiang Li; Chaoting Zhang; Dong Hang; Tao Ning; Chuanhai Guo; Yongmei Liang; Ruiping Xu; Lixin Zhang; Hong Cai; Yang Ke
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

10.  A cross-sectional study on the concordance between vaginal HPV DNA detection and type-specific antibodies in a multi-ethnic cohort of women from Amsterdam, the Netherlands - the HELIUS study.

Authors:  Alexandra Kovaleva; Catharina J Alberts; Tim Waterboer; Angelika Michel; Marieke B Snijder; Wilma Vermeulen; Liza Coyer; Maria Prins; Maarten Schim van der Loeff
Journal:  BMC Infect Dis       Date:  2016-09-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.